Psychopharmacology

, Volume 182, Issue 4, pp 551–561 | Cite as

Anti-nociception is selectively enhanced by parallel inhibition of multiple subtypes of monoamine transporters in rat models of persistent and neuropathic pain

  • Louise H. Pedersen
  • Alexander N. Nielsen
  • Gordon Blackburn-Munro
Original Investigation

Abstract

Rationale

Neuropathic pain is characterised by hyperexcitability within nociceptive pathways that manifests behaviourally as allodynia and hyperalgesia and remains difficult to treat with standard analgesics. However, antidepressants have shown reasonable preclinical and clinical anti-nociceptive efficacy against signs and symptoms of neuropathic pain.

Objectives

To ascertain whether inhibition of serotonin (5-HT) and/or noradrenaline (NA) and/or dopamine (DA) re-uptake preferentially mediates superior anti-nociception in preclinical pain models.

Methods

The 5-HT re-uptake inhibitor fluoxetine (3–30 mg/kg), the NA re-uptake inhibitor reboxetine (3–30 mg/kg), the dual 5-HT and NA re-uptake inhibitor venlafaxine (3–100 mg/kg) and the dual DA and NA re-uptake inhibitor bupropion (3–30 mg/kg) were tested after intraperitoneal administration in rat models of acute, persistent and neuropathic pain.

Results

Reboxetine and venlafaxine dose-dependently attenuated second-phase flinching in the formalin test; fluoxetine attenuated flinching only at the highest dose tested, whereas bupropion was ineffective. In the chronic constriction injury (CCI) and spinal nerve ligation models of neuropathic pain, hindpaw mechanical allodynia was significantly attenuated by fluoxetine and particularly by bupropion. Reboxetine and venlafaxine were completely ineffective. In contrast, reboxetine and venlafaxine reversed thermal hyperalgesia in CCI rats, whereas bupropion and fluoxetine were either minimally effective or ineffective. Fluoxetine, reboxetine and venlafaxine transiently increased the tail-flick latency in uninjured animals. Anti-nociceptive doses of drugs had no effect on motor function.

Conclusions

Combined re-uptake inhibition of 5-HT and NA appears to confer a greater degree of anti-nociception in animal models of experimental pain than single mechanism of action inhibitors. The selective attenuation of mechanical allodynia by bupropion suggests that the additional re-uptake of DA may further augment 5-HT/NA re-uptake mediated anti-nociception after nerve injury.

Keywords

Allodynia Antidepressant Bupropion Chronic constriction injury Formalin test Fluoxetine Hyperalgesia Reboxetine Venlafaxine 

Notes

Acknowledgements

LHP was supported by the Danish Academy of Technical Sciences. Expert technical assistance was provided by Nete Ibsen, Helene Dyhr Pedersen and Paula Lindberg.

References

  1. Abdi S, Lee DH, Chung JM (1998) The anti-allodynic effects of amitriptyline, gabapentin, and lidocaine in a rat model of neuropathic pain. Anesth Analg 87:1360–1366PubMedCrossRefGoogle Scholar
  2. Arnold LM, Lu Y, Crofford LJ, Wohlreich M, Detke MJ, Iyengar S, Goldstein DJ (2004) A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum 50:2974–2984CrossRefPubMedGoogle Scholar
  3. Backonja M, Beydoun A, Edwards KR, Schwartz SL, Fonseca V, Hes M, LaMoreaux L, Garofalo E (1998) Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA 280:1831–1836CrossRefPubMedGoogle Scholar
  4. Bennett GJ, Xie YK (1988) A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man. Pain 33:87–107CrossRefPubMedGoogle Scholar
  5. Blackburn-Munro G (2004) Pain-like behaviours in animals—how human are they? Trends Pharmacol Sci 25:299–305CrossRefPubMedGoogle Scholar
  6. Blackburn-Munro G, Bomholt SF, Erichsen HK (2004) Behavioural effects of the novel AMPA/GluR5 selective receptor antagonist NS1209 after systemic administration in animal models of experimental pain. Neuropharmacology 47:351–362CrossRefPubMedGoogle Scholar
  7. Bomholt SF, Mikkelsen JD, Blackburn-Munro G (2005) Antinociceptive effects of the antidepressants amitriptyline, duloxetine, mirtazapine and citalopram in animal models of acute, persistent and neuropathic pain. Neuropharmacology 48:252–263CrossRefPubMedGoogle Scholar
  8. Briley M (2003) New hope in the treatment of painful symptoms in depression. Curr Opin Investig Drugs 4:42–45PubMedGoogle Scholar
  9. Burgess SE, Gardell LR, Ossipov MH, Malan TP Jr, Vanderah TW, Lai J, Porreca F (2002) Time-dependent descending facilitation from the rostral ventromedial medulla maintains, but does not initiate, neuropathic pain. J Neurosci 22:5129–5136PubMedGoogle Scholar
  10. Bymaster FP, McNamara RK, Tran PV (2003) New approaches to developing antidepressants by enhancing monoaminergic neurotransmission. Expert Opin Investig Drugs 12:531–543CrossRefPubMedGoogle Scholar
  11. Canavero S, Bonicalzi V, Paolotti R (2002) Reboxetine for central pain: a single-blind prospective study. Clin Neuropharmacol 25:238–239CrossRefPubMedGoogle Scholar
  12. Coderre TJ, Fundytus ME, McKenna JE, Dalal S, Melzack R (1993) The formalin test: a validation of the weighted-scores method of behavioural pain rating. Pain 54:43–50CrossRefPubMedGoogle Scholar
  13. Cooper BR, Wang CM, Cox RF, Norton R, Shea V, Ferris RM (1994) Evidence that the acute behavioral and electrophysiological effects of bupropion (Wellbutrin) are mediated by a noradrenergic mechanism. Neuropsychopharmacology 11:133–141PubMedGoogle Scholar
  14. Dworkin RH, Backonja M, Rowbotham MC, Allen RR, Argoff CR, Bennett GJ, Bushnell MC, Farrar JT, Galer BS, Haythornthwaite JA, Hewitt DJ, Loeser JD, Max MB, Saltarelli M, Schmader KE, Stein C, Thompson D, Turk DC, Wallace MS, Watkins LR, Weinstein SM (2003) Advances in neuropathic pain: diagnosis, mechanisms, and treatment recommendations. Arch Neurol 60:1524–1534CrossRefPubMedGoogle Scholar
  15. Field MJ, Oles RJ, Lewis AS, McCleary S, Hughes J, Singh L (1997) Gabapentin (neurontin) and S-(+)-3-isobutylgaba represent a novel class of selective antihyperalgesic agents. Br J Pharmacol 121:1513–1522PubMedCrossRefGoogle Scholar
  16. Field MJ, Gonzalez MI, Tallarida RJ, Singh L (2002) Gabapentin and the neurokinin(1) receptor antagonist CI-1021 act synergistically in two rat models of neuropathic pain. J Pharmacol Exp Ther 303:730–735CrossRefPubMedGoogle Scholar
  17. Fields HL, Basbaum AI (1999) Central nervous system mechanisms of pain modulation. In: Wall PD, Melzack R (eds) Textbook of pain, 4th edn. Churchill-Livingstone, Edinburgh, pp 309–330Google Scholar
  18. Gardell LR, Vanderah TW, Gardell SE, Wang R, Ossipov MH, Lai J, Porreca F (2003) Enhanced evoked excitatory transmitter release in experimental neuropathy requires descending facilitation. J Neurosci 23:8370–8379PubMedGoogle Scholar
  19. Hajos M, Fleishaker JC, Filipiak-Reisner JK, Brown MT, Wong EH (2004) The selective norepinephrine reuptake inhibitor antidepressant reboxetine: pharmacological and clinical profile. CNS Drug Rev 10:23–44PubMedCrossRefGoogle Scholar
  20. Hunter JC, Gogas KR, Hedley LR, Jacobson LO, Kassotakis L, Thompson J, Fontana DJ (1997) The effect of novel anti-epileptic drugs in rat experimental models of acute and chronic pain. Eur J Pharmacol 324:153–160PubMedCrossRefGoogle Scholar
  21. Iyengar S, Webster AA, Hemrick-Luecke SK, Xu JY, Simmons RM (2004) Efficacy of duloxetine, a potent and balanced serotonin-norepinephrine reuptake inhibitor in persistent pain models in rats. J Pharmacol Exp Ther 311:576–584CrossRefPubMedGoogle Scholar
  22. Jett MF, McGuirk J, Waligora D, Hunter JC (1997) The effects of mexiletine, desipramine and fluoxetine in rat models involving central sensitization. Pain 69:161–169CrossRefPubMedGoogle Scholar
  23. Kim SH, Chung JM (1992) An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat. Pain 50:355–363CrossRefPubMedGoogle Scholar
  24. Koch S, Hemrick-Luecke SK, Thompson LK, Evans DC, Threlkeld PG, Nelson DL, Perry KW, Bymaster FP (2003) Comparison of effects of dual transporter inhibitors on monoamine transporters and extracellular levels in rats. Neuropharmacology 45:935–944CrossRefPubMedGoogle Scholar
  25. Lang E, Hord AH, Denson D (1996) Venlafaxine hydrochloride (Effexor) relieves thermal hyperalgesia in rats with an experimental mononeuropathy. Pain 68:151–155CrossRefPubMedGoogle Scholar
  26. Le Bars D, Gozariu M, Cadden SW (2001) Animal models of nociception. Pharmacol Rev 53:597–652PubMedGoogle Scholar
  27. Luo ZD, Calcutt NA, Higuera ES, Valder CR, Song YH, Svensson CI, Myers RR (2002) Injury type-specific calcium channel alpha 2 delta-1 subunit up-regulation in rat neuropathic pain models correlates with antiallodynic effects of gabapentin. J Pharmacol Exp Ther 303:1199–1205CrossRefPubMedGoogle Scholar
  28. MacFarlane BV, Wright A, O'Callaghan J, Benson HA (1997) Chronic neuropathic pain and its control by drugs. Pharmacol Ther 75:1–19CrossRefPubMedGoogle Scholar
  29. Marchand F, Alloui A, Chapuy E, Jourdan D, Pelissier T, Ardid D, Hernandez A, Eschalier A (2003) Evidence for a monoamine mediated, opioid-independent, antihyperalgesic effect of venlafaxine, a non-tricyclic antidepressant, in a neurogenic pain model in rats. Pain 103:229–235CrossRefPubMedGoogle Scholar
  30. Martin WJ, Gupta K, Loo CM, Rohde DS, Basbaum AI (1999) Differential effects of neurotoxic destruction of descending noradrenergic pathways on acute and persistent nociceptive processing. Pain 80:57–65CrossRefPubMedGoogle Scholar
  31. Max MB, Culnane M, Schafer SC, Gracely RH, Walther DJ, Smoller B, Dubner R (1987) Amitriptyline relieves diabetic neuropathy pain in patients with normal or depressed mood. Neurology 37:589–596PubMedGoogle Scholar
  32. Millan MJ (2002) Descending control of pain. Prog Neurobiol 66:355–474CrossRefPubMedGoogle Scholar
  33. Miller DK, Wong EH, Chesnut MD, Dwoskin LP (2002) Reboxetine: functional inhibition of monoamine transporters and nicotinic acetylcholine receptors. J Pharmacol Exp Ther 302:687–695CrossRefPubMedGoogle Scholar
  34. Morello CM, Leckband SG, Stoner CP, Moorhouse DF, Sahagian GA (1999) Randomized double-blind study comparing the efficacy of gabapentin with amitriptyline on diabetic peripheral neuropathy pain. Arch Intern Med 159:1931–1937CrossRefPubMedGoogle Scholar
  35. Nayebi AR, Hassanpour M, Rezazadeh H (2001) Effect of chronic and acute administration of fluoxetine and its additive effect with morphine on the behavioural response in the formalin test in rats. J Pharm Pharmacol 53:219–225CrossRefPubMedGoogle Scholar
  36. Nomikos GG, Damsma G, Wenkstern D, Fibiger HC (1989) Acute effects of bupropion on extracellular dopamine concentrations in rat striatum and nucleus accumbens studied by in vivo microdialysis. Neuropsychopharmacology 2:273–279CrossRefPubMedGoogle Scholar
  37. Obata H, Conklin D, Eisenach JC (2005) Spinal noradrenaline transporter inhibition by reboxetine and Xen2174 reduces tactile hypersensitivity after surgery in rats. Pain 113:271–276CrossRefPubMedGoogle Scholar
  38. Otsuka N, Kiuchi Y, Yokogawa F, Masuda Y, Oguchi K, Hosoyamada A (2001) Antinociceptive efficacy of antidepressants: assessment of five antidepressants and four monoamine receptors in rats. J Anesth 15:154–158CrossRefPubMedGoogle Scholar
  39. Porreca F, Ossipov MH, Gebhart GF (2002) Chronic pain and medullary descending facilitation. Trends Neurosci 25:319–325CrossRefPubMedGoogle Scholar
  40. Ren K, Dubner R (2002) Descending modulation in persistent pain: an update. Pain 100:1–6CrossRefPubMedGoogle Scholar
  41. Rowbotham M, Harden N, Stacey B, Bernstein P, Magnus-Miller L (1998) Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. JAMA 280:1837–1842CrossRefPubMedGoogle Scholar
  42. Rowbotham MC, Goli V, Kunz NR, Lei D (2004) Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study. Pain 110:697–706CrossRefPubMedGoogle Scholar
  43. Sayar K, Aksu G, Ak I, Tosun M (2003) Venlafaxine treatment of fibromyalgia. Ann Pharmacother 37:1561–1565PubMedCrossRefGoogle Scholar
  44. Semenchuk MR, Sherman S, Davis B (2001) Double-blind, randomized trial of bupropion SR for the treatment of neuropathic pain. Neurology 57:1583–1588PubMedGoogle Scholar
  45. Sindrup SH, Jensen TS (2001) Antidepressants in the treatment of neuropathic pain. In: Hansson PT, Fields HL, Hill RG, Marchettini P (eds) Neuropathic pain: pathophysiology and treatment. IASP Press, Seattle, pp 169–183Google Scholar
  46. Sindrup SH, Bjerre U, Dejgaard A, Brosen K, Aaes-Jorgensen T, Gram LF (1992) The selective serotonin reuptake inhibitor citalopram relieves the symptoms of diabetic neuropathy. Clin Pharmacol Ther 52:547–552PubMedCrossRefGoogle Scholar
  47. Sindrup SH, Bach FW, Madsen C, Gram LF, Jensen TS (2003) Venlafaxine versus imipramine in painful polyneuropathy: a randomized, controlled trial. Neurology 60:1284–1289PubMedGoogle Scholar
  48. Singh L, Field MJ, Ferris P, Hunter JC, Oles RJ, Williams RG, Woodruff GN (1996) The antiepileptic agent gabapentin (Neurontin) possesses anxiolytic-like and antinociceptive actions that are reversed by D-serine. Psychopharmacology 127:1–9PubMedGoogle Scholar
  49. Smith AJ (1998) The analgesic effects of selective serotonin reuptake inhibitors. J Psychopharmacol 12:407–413PubMedCrossRefGoogle Scholar
  50. Stahl SM (1998) Basic psychopharmacology of antidepressants, part 1: antidepressants have seven distinct mechanisms of action. J Clin Psychiatry 59(Suppl 4):5–14PubMedGoogle Scholar
  51. Stahl SM, Pradko JF, Haight BR, Modell JG, Rockett CB, Learned-Coughlin S (2004) A review of the neuropharmacology of bupropion, a dual norepinephrine and dopamine reuptake inhibitor. Prim Care Companion J Clin Psychiat 6:159–166Google Scholar
  52. Vitton O, Gendreau M, Gendreau J, Kranzler J, Rao SG (2004) A double-blind placebo-controlled trial of milnacipran in the treatment of fibromyalgia. Hum Psychopharmacol 19(Suppl 1):S27–S35CrossRefPubMedGoogle Scholar
  53. Woolf CJ, Salter MW (2000) Neuronal plasticity: increasing the gain in pain. Science 288:1765–1769PubMedCrossRefGoogle Scholar
  54. Wong EH, Sonders MS, Amara SG, Tinholt PM, Piercey MF, Hoffmann WP, Hyslop DK, Franklin S, Porsolt RD, Bonsignori A, Carfagna N, McArthur RA (2000) Reboxetine: a pharmacologically potent, selective, and specific norepinephrine reuptake inhibitor. Biol Psychiatry 47:818–829CrossRefPubMedGoogle Scholar
  55. Yaksh TL, Ozaki G, McCumber D, Rathbun M, Svensson C, Malkmus S, Yaksh MC (2001) An automated flinch detecting system for use in the formalin nociceptive bioassay. J Appl Physiol 90:2386–2402PubMedGoogle Scholar
  56. Zimmermann M (1983) Ethical guidelines for investigations of experimental pain in conscious animals. Pain 16:109–110CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2005

Authors and Affiliations

  • Louise H. Pedersen
    • 1
  • Alexander N. Nielsen
    • 1
  • Gordon Blackburn-Munro
    • 1
  1. 1.Department of PharmacologyNeuroSearch A/SBallerupDenmark

Personalised recommendations